从发现到影响: augmented renal clearance 与抗生素给药的两十年
本文回顾了 augmented renal clearance(ARC)的发现过程及其对抗生素治疗的影响。ARC 定义肌酐清除率 >130 mL/min/1.73 m²,在血肌酐正常的危重患者中发生率为 65%-80%,是抗生素治疗失败和耐药选择的重要风险因素。治疗药物监测仍是确保抗生素充分暴露的最可靠方法。
要点
- ARC 指肌酐清除率 >130 mL/min/1.73 m²,常见于脓毒症、创伤或烧伤的年轻危重患者。
- ARC 可导致经肾消除抗生素清除增加、暴露降低,增加治疗失败和耐药风险。
- 治疗药物监测是确保 ARC 患者抗生素充分暴露的最可靠方法。
核心结论
- ARC 是危重患者抗生素给药中显著但被低估的挑战,治疗药物监测仍是确保充分暴露的最可靠方法。
研究设计与样本
- 叙述性评论,探讨 ARC 的发现、临床意义、诊断挑战及危重患者抗生素给药管理策略,并提出未来研究重点。
主要发现
- ARC 最早于 1990 年代末在南非 Baragwanath 医院 ICU 患者中注意到,肌酐清除率意外高达 >200 mL/min。
- 后续药代动力学研究证实抗生素清除升高、全身暴露降低。
- ARC 定义为肌酐清除率 >130 mL/min/1.73 m²,在血肌酐正常的危重患者中发生率为 65%-80%,尤其见于脓毒症、创伤或烧伤的年轻患者。
- ARC 源于全身炎症反应时心输出量和肾血流量增加,可在 ICU 入住后持续数周,影响所有经肾消除药物。
- 除非直接测量某种形式的肌酐清除率,ARC 常未被诊断,且是抗生素失败和耐药选择的主要风险因素。
关键数值与推荐
- ARC 定义为肌酐清除率 >130 mL/min/1.73 m²。
- ARC 在血肌酐正常的危重患者中发生率为 65%-80%。
临床怎么用
- 对高危危重患者应直接测量肌酐清除率以识别 ARC。
- 对 ARC 患者应使用治疗药物监测确保抗生素充分暴露。
局限性
- 本文为叙述性评论,未报告系统检索范围或定量合并分析。
- 未来需验证预测模型、更简单诊断方法和高危人群的循证给药指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Renal function monitoring traditionally focuses on detecting impairment to prevent antibiotic toxicity. However, augmented renal clearance (ARC) represents the opposite challenge-enhanced elimination causing subtherapeutic drug concentrations. The aim of this review is to describe ARC's discovery and its impact on antibiotic therapy over two decades. METHODS: Narrative commentary examining ARC's discovery, clinical significance, diagnostic challenges and management strategies for antibiotic dosing in critically ill patients, with future research priorities. RESULTS: ARC was first noted in the late 1990s at Baragwanath Hospital, South Africa, where unexpectedly high creatinine clearance rates (>200 mL/min) were measured in ICU patients. Subsequent pharmacokinetic studies confirmed elevated antibiotic clearance with reduced systemic exposures. ARC, defined as creatinine clearance of >130 mL/min/1.73 m2, occurs in 65%-80% of critically ill patients with normal serum creatinine, particularly younger patients with sepsis, trauma or burns. The phenomenon results from increased cardiac output and renal blood flow during systemic inflammatory responses, can persist for weeks after ICU admission, and affects all renally eliminated drugs. ARC is often undiagnosed unless some form of creatine clearance is directly measured. Importantly, ARC is a major risk factor for antibiotic failure and resistance selection. CONCLUSIONS: ARC represents a significant but underrecognized challenge affecting antibiotic dosing in critically ill patients. Therapeutic drug monitoring remains the most reliable method to ensure adequate antibiotic exposure. Future research priorities include validated predictive models, simpler diagnostic methods and evidence-based dosing guidelines for high-risk populations.
引用
- Lipman J, Lewis RE. The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing. J Antimicrob Chemother. 2025. PMID: 41077962. doi:10.1093/jac/dkaf378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。